Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga
Condition: Type 2 Diabetes Mellitus
MeSH terms: Diabetes Mellitus; Diabetes Mellitus, Type 2
Intervention: insulin glargine; metformin; Forxiga; Lifestyle therapy
Intervention description: Dose is titrated to achieve fasting normoglycemia; Dose is titrated to 1 g bid or maximal tolerated dose; Dose is titrated to 10 mg po daily or maximal tolerated dose; Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
Intervention MeSH terms: Metformin; Insulin Glargine; Dapagliflozin
Phase: Phase 4
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Enrollment: 154.0
Sex: All
Minimum age: 30 Years
Maximum age: 80 Years
Healthy volunteers: No
Keywords: Diabetes; Insulin; Glargine; Metformin; Forxiga; Diet; Exercise; Lifestyle

Summary:

      The purpose of the study is to determine whether in patients with early type 2 diabetes, a
      short-term intensive metabolic intervention comprising Forxiga, metformin, basal insulin
      glargine and lifestyle approaches will be superior to standard diabetes therapy in achieving
      sustained diabetes remission.
    

Eligibility criteria:

        Inclusion Criteria:

          1. men and women 30-80 years of age inclusive;

          2. type 2 diabetes mellitus diagnosed by a physician within 8 years prior to patient
             enrollment;

          3. anti-diabetic drug regimen (either drug or dose of drug) unchanged during 8 weeks
             prior to screening and randomization;

          4. HbA1C 6.5-9.5% inclusive on no hypoglycemic agents or HbA1C ≤ 8.0% on up to 2
             glucose-lowering agents;

          5. body mass index ≥ 23 kg/m2;

          6. ability and willingness to perform self-monitoring of capillary blood glucose (SMBG);

          7. ability and willingness to self-inject insulin;

          8. provision of informed consent.

        Exclusion Criteria:

          1. current use of insulin therapy;

          2. history of hypoglycemia unawareness, or severe hypoglycemia requiring assistance;

          3. history of end-stage renal disease or renal dysfunction as evidenced by eGFR<60
             mL/min/1.73 m2 by MDRD formula;

          4. history of lactic acidosis or diabetic ketoacidosis;

          5. active liver disease or elevated alanine transferase (ALT) levels ≥ 2.5 times upper
             limit of normal at the time of enrollment;

          6. history of bladder cancer or undiagnosed hematuria;

          7. history of breast cancer;

          8. history of polycythemia;

          9. evidence of volume depletion or hypotension (systolic blood pressure < 90 mmHg);

         10. systolic blood pressure > 180 mmHg or diastolic blood pressure > 105 mmHg;

         11. diagnosed cardiovascular disease (unless cleared for a moderate intensity exercise
             program by a specialist) including:

               1. any history of acute coronary syndrome, hospitalization for unstable angina,
                  myocardial infarction, or revascularization with coronary artery bypass grafting
                  or percutaneous coronary intervention;

               2. other evidence of coronary artery disease;

               3. peripheral vascular disease, valvular heart disease, cardiomyopathy, aortic
                  dissection, tachyarrhythmias, bradyarrhythmias, prior stroke or TIA;

               4. prior hospitalization for heart failure; or

               5. ECG findings concerning for ischemic heart disease (i.e. pathological Q-waves,
                  ST-segment-T-wave abnormalities in contiguous leads, left anterior hemiblock,
                  left bundle branch block, second or third degree atrioventricular block).

         12. dependence on oxygen;

         13. history of any disease requiring frequent intermittent or continuous systemic
             glucocorticoid treatment;

         14. history of bariatric surgery, or planned bariatric surgery in the next 1.5 years;

         15. history of any major illness with a life expectancy of < 3 years;

         16. history of injury or any other condition that significantly limits participant's
             ability to achieve moderate levels of physical activity;

         17. any history of excessive alcohol intake, acute or chronic;

         18. currently pregnant, or breastfeeding, or not using a reliable method of birth control
             for the duration of the trial in all females with childbearing potential; reliable
             methods of birth control include oral contraceptive (birth control pill), hormonal
             injection, implant, patch, or vaginal ring, intrauterine device, barrier method
             (condom and spermicide), tubal ligation, partner vasectomy or abstinence;

         19. known hypersensitivity to metformin, Forxiga, or insulin glargine.